Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? | Zendy

Bryan L. Roth | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?

Author(s) -

Bryan L. Roth

Publication year - 2006

Publication title -

dialogues in clinical neuroscience

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.11

H-Index - 87

eISSN - 1958-5969

pISSN - 1294-8322

DOI - 10.31887/dcns.2006.8.3/broth

Subject(s) - druggability , drug discovery , antipsychotic , schizophrenia (object oriented programming) , drug , antipsychotic drug , pharmacology , computational biology , medicine , biology , bioinformatics , psychiatry , genetics , gene

This review summarizes the various conceptual paradigms for treating schizophrenia, and indicates how molecular biology and drug discovery technologies can accelerate the development of new medications. As yet, there is no convincing data that a crucial druggable molecular target exists which, if targeted, would yield medications with efficacies greater than any currently available. It is suggested, instead, that drugs which interact with a multiplicity of molecular targets are likely to show greater efficacy in treating the core symptoms of schizophrenia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research